Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI).
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
06 07 2020
06 07 2020
Historique:
received:
21
04
2020
accepted:
23
06
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
24
3
2021
Statut:
epublish
Résumé
Acyl coenzyme A binding protein (ACBP), also known as diazepam binding inhibitor (DBI) is a multifunctional protein with an intracellular action (as ACBP), as well as with an extracellular role (as DBI). The plasma levels of soluble ACBP/DBI are elevated in human obesity and reduced in anorexia nervosa. Accumulating evidence indicates that genetic or antibody-mediated neutralization of ACBP/DBI has anorexigenic effects, thus inhibiting food intake and inducing lipo-catabolic reactions in mice. A number of anorexiants have been withdrawn from clinical development because of their side effects including an increase in depression and suicide. For this reason, we investigated the psychiatric impact of ACBP/DBI in mouse models and patient cohorts. Intravenously (i.v.) injected ACBP/DBI protein conserved its orexigenic function when the protein was mutated to abolish acyl coenzyme A binding, but lost its appetite-stimulatory effect in mice bearing a mutation in the γ2 subunit of the γ-aminobutyric acid (GABA) A receptor (GABA
Identifiants
pubmed: 32632162
doi: 10.1038/s41419-020-2716-5
pii: 10.1038/s41419-020-2716-5
pmc: PMC7338362
doi:
Substances chimiques
Diazepam Binding Inhibitor
0
Receptors, GABA-A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
502Références
Tonon, M.-C. et al. Endozepines and their receptors: structure, functions and pathophysiological significance. Pharmacol. Ther.208, 107386 (2020).
pubmed: 31283949
doi: 10.1016/j.pharmthera.2019.06.008
Bravo-San Pedro, J. M. et al. Acyl-CoA-binding protein is a lipogenic factor that triggers food intake and obesity. Cell Metab.30, 1171 (2019).
pubmed: 31801056
doi: 10.1016/j.cmet.2019.10.011
Conti, E. et al. Reduced fasting plasma levels of diazepam-binding inhibitor in adolescents with anorexia nervosa. Int. J. Eat. Disord.46, 626–629 (2013).
pubmed: 23625555
doi: 10.1002/eat.22129
Clavier, T. et al. Increased plasma levels of endozepines, endogenous ligands of benzodiazepine receptors, during systemic inflammation: a prospective observational study. Crit. Care Lond. Engl.18, 633 (2014).
doi: 10.1186/s13054-014-0633-7
Dandona, P. et al. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab.83, 2907–2910 (1998).
pubmed: 9709967
Hotamisligil, G. S. Inflammation, metaflammation and immunometabolic disorders. Nature542, 177–185 (2017).
pubmed: 28179656
doi: 10.1038/nature21363
Manjithaya, R., Anjard, C., Loomis, W. F. & Subramani, S. Unconventional secretion of Pichia pastoris Acb1 is dependent on GRASP protein, peroxisomal functions, and autophagosome formation. J. Cell Biol.188, 537–546 (2010).
pubmed: 20156962
pmcid: 2828923
doi: 10.1083/jcb.200911149
Charmpilas, N. et al. Acyl-CoA-binding protein (ACBP): a phylogenetically conserved appetite stimulator. Cell Death Dis.11, 7 (2020).
pubmed: 31907349
pmcid: 6944704
doi: 10.1038/s41419-019-2205-x
Anjard, C. & Loomis, W. F. Peptide signaling during terminal differentiation of Dictyostelium. Proc. Natl Acad. Sci. USA102, 7607–7611 (2005).
pubmed: 15897458
doi: 10.1073/pnas.0501820102
Ryuda, M. et al. Identification of a novel gene, anorexia, regulating feeding activity via insulin signaling in Drosophila melanogaster. J. Biol. Chem.286, 38417–38426 (2011).
pubmed: 21917925
pmcid: 3207462
doi: 10.1074/jbc.M111.267344
Bravo-San Pedro, J. M., Sica, V. & Kroemer, G. The elusive ‘hunger protein’: an appetite-stimulatory factor that is overabundant in human obesity. Mol. Cell. Oncol.6, e1667193 (2019).
pubmed: 31692883
doi: 10.1080/23723556.2019.1667193
pmcid: 6816372
Pedro, J. M. B.-S., Sica, V., Madeo, F. & Kroemer, G. Acyl-CoA-binding protein (ACBP): the elusive ‘hunger factor’ linking autophagy to food intake. Cell Stress3, 312–318 (2019).
pubmed: 31656948
pmcid: 6789435
doi: 10.15698/cst2019.10.200
Henry, C. et al. Outcomes for bipolar patients assessed in the French expert center network: A 2-year follow-up observational study (FondaMental Advanced Centers of Expertise for Bipolar Disorder [FACE-BD]). Bipolar Disord. 19, 651–660 (2017).
Godin, O. et al. Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort. Schizophr. Res.168, 388–394 (2015).
pubmed: 26255568
doi: 10.1016/j.schres.2015.07.047
Godin, O. et al. Metabolic syndrome and illness severity predict relapse at 1-year follow-up in schizophrenia: the FACE-SZ cohort. J. Clin. Psychiatry79, 17m12007 (2018).
Rudolph, U. & Möhler, H. GABAA receptor subtypes: therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu. Rev. Pharmacol. Toxicol.54, 483–507 (2014).
pubmed: 24160694
doi: 10.1146/annurev-pharmtox-011613-135947
Setiawan, E. et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry72, 268–275 (2015).
pubmed: 25629589
pmcid: 4836849
doi: 10.1001/jamapsychiatry.2014.2427
Marino, R. A. M. et al. Control of food approach and eating by a GABAergic projection from lateral hypothalamus to dorsal pons. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.1909340117 (2020).
doi: 10.1073/pnas.1909340117
pubmed: 32493750
Bhandage, A. K. et al. GABA regulates release of inflammatory cytokines from peripheral blood mononuclear cells and CD4+ T cells and is immunosuppressive in type 1 diabetes. EBioMedicine30, 283–294 (2018).
pubmed: 29627388
pmcid: 5952354
doi: 10.1016/j.ebiom.2018.03.019
Wulff, P. et al. From synapse to behavior: rapid modulation of defined neuronal types with engineered GABAA receptors. Nat. Neurosci.10, 923–929 (2007).
pubmed: 17572671
pmcid: 2092503
doi: 10.1038/nn1927
Kragelund, B. B. et al. Conserved residues and their role in the structure, function, and stability of acyl-coenzyme A binding protein. Biochemistry38, 2386–2394 (1999).
pubmed: 10029532
doi: 10.1021/bi982427c
Fregeac, J. et al. Loss of the neurodevelopmental disease-associated gene miR-146a impairs neural progenitor differentiation and causes learning and memory deficits. Mol. Autism11, 22 (2020).
pubmed: 32228681
pmcid: 7106595
doi: 10.1186/s13229-020-00328-3
Krishnan, V. & Nestler, E. J. Animal models of depression: molecular perspectives. Curr. Top. Behav. Neurosci.7, 121–147 (2011).
pubmed: 21225412
pmcid: 3270071
doi: 10.1007/7854_2010_108
Alberti, K. G. M. M., Zimmet, P. & Shaw, J. IDF Epidemiology Task Force Consensus Group The metabolic syndrome-a new worldwide definition. Lancet366, 1059–1062 (2005).
pubmed: 16182882
doi: 10.1016/S0140-6736(05)67402-8
Larsen, M. K., Tuck, S., Faergeman, N. J. & Knudsen, J. MAA-1, a novel acyl-CoA-binding protein involved in endosomal vesicle transport in Caenorhabditis elegans. Mol. Biol. Cell17, 4318–4329 (2006).
pubmed: 16870706
pmcid: 1635345
doi: 10.1091/mbc.e06-01-0035
Dumitru, I., Neitz, A., Alfonso, J. & Monyer, H. Diazepam binding inhibitor promotes stem cell expansion controlling environment-dependent neurogenesis. Neuron94, 125–137.e5 (2017).
pubmed: 28343864
doi: 10.1016/j.neuron.2017.03.003
Rudolph, U. & Knoflach, F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov.10, 685–697 (2011).
pubmed: 21799515
pmcid: 3375401
doi: 10.1038/nrd3502
Srivastava, G. & Apovian, C. M. Current pharmacotherapy for obesity. Nat. Rev. Endocrinol.14, 12–24 (2018).
pubmed: 29027993
doi: 10.1038/nrendo.2017.122
Galaj, E. & Xi, Z.-X. Potential of cannabinoid receptor ligands as treatment for substance use disorders. CNS Drugs33, 1001–1030 (2019).
pubmed: 31549358
doi: 10.1007/s40263-019-00664-w
pmcid: 7451396
Belzung, C., Misslin, R., Vogel, E., Dodd, R. H. & Chapouthier, G. Anxiogenic effects of methyl-beta-carboline-3-carboxylate in a light/dark choice situation. Pharmacol. Biochem. Behav.28, 29–33 (1987).
pubmed: 3116561
doi: 10.1016/0091-3057(87)90006-2
Ennaceur, A. Tests of unconditioned anxiety—pitfalls and disappointments. Physiol. Behav.135, 55–71 (2014).
pubmed: 24910138
doi: 10.1016/j.physbeh.2014.05.032
Engel, O. et al. Imepitoin shows benzodiazepine-like effects in models of anxiety. Front. Pharm.9, 1225 (2018).
doi: 10.3389/fphar.2018.01225
Silva, M. T. & Calil, H. M. Screening hallucinogenic drugs: systematic study of three behavioral tests. Psychopharmacologia42, 163–171 (1975).
pubmed: 1080571
doi: 10.1007/BF00429548
Stanford, S. C. The Open Field Test: reinventing the wheel. J. Psychopharmacol.21, 134–135 (2007).
pubmed: 17329288
doi: 10.1177/0269881107073199
Nagatani, T., Yamamoto, T., Sugihara, T. & Ueki, S. The effect of agonists at the GABA-benzodiazepine receptor complex on the duration of immobility of mice in the forced swimming test. Eur. J. Pharmacol.142, 17–22 (1987).
pubmed: 2891543
doi: 10.1016/0014-2999(87)90648-0
Van der Meersch-Mougeot, V. et al. Benzodiazepines reverse the anti-immobility effect of antidepressants in the forced swimming test in mice. Neuropharmacology32, 439–446 (1993).
pubmed: 8100621
doi: 10.1016/0028-3908(93)90167-2
Sica, V., Martins, I., Motiño, O., Bravo-San Pedro, J. M. & Kroemer, G. Antibody-mediated neutralization of ACBP/DBI has anorexigenic and lipolytic effects. Adipocyte9, 116–119 (2020).
pubmed: 32157940
pmcid: 7153538
doi: 10.1080/21623945.2020.1736734
Kobayashi, H., Maeda, M., Hayata, T. & Kawashima, Y. Clinical study of combination chemotherapy with CDDP, ADM and CPM for ovarian cancer. Nihon Gan Chiryo Gakkai Shi23, 829–836 (1988).
pubmed: 3204307
Ujjainwala, A. L., Courtney, C. D., Rhoads, S. G., Rhodes, J. S. & Christian, C. A. Genetic loss of diazepam binding inhibitor in mice impairs social interest. Genes Brain Behav.17, e12442 (2018).
pubmed: 29193847
doi: 10.1111/gbb.12442
Guidotti, A. et al. Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc. Natl Acad. Sci. USA80, 3531–3535 (1983).
pubmed: 6304714
doi: 10.1073/pnas.80.11.3531
De Mateos-Verchere, J. G., Leprince, J., Tonon, M. C., Vaudry, H. & Costentin, J. The octadecaneuropeptide ODN induces anxiety in rodents: possible involvement of a shorter biologically active fragment. Peptides19, 841–848 (1998).
pubmed: 9663449
doi: 10.1016/S0196-9781(98)00037-0
Cavaillon, J. M. & Haeffner-Cavaillon, N. The role of serum in interleukin 1 production by human monocytes activated by endotoxins and their polysaccharide moieties. Immunol. Lett.10, 35–41 (1985).
pubmed: 2861158
doi: 10.1016/0165-2478(85)90047-1
de Mateos-Verchere, J. G., Leprince, J., Tonon, M. C., Vaudry, H. & Costentin, J. The octadecaneuropeptide [diazepam-binding inhibitor (33-50)] exerts potent anorexigenic effects in rodents. Eur. J. Pharmacol. 414, 225–231 (2001).
do Rego, J.-C. et al. Pharmacological characterization of the receptor mediating the anorexigenic action of the octadecaneuropeptide: evidence for an endozepinergic tone regulating food intake. Neuropsychopharmacology32, 1641–1648 (2007).
pubmed: 17151595
doi: 10.1038/sj.npp.1301280
Matsuda, K. et al. Effect of the diazepam-binding inhibitor-derived peptide, octadecaneuropeptide, on food intake in goldfish. Neuroscience150, 425–432 (2007).
pubmed: 17936516
doi: 10.1016/j.neuroscience.2007.09.012